Last reviewed · How we verify
AB-106, Rifampicin
Inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase
Inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase Used for Tuberculosis.
At a glance
| Generic name | AB-106, Rifampicin |
|---|---|
| Sponsor | Nuvation Bio Inc. |
| Drug class | Bactericidal antibiotic |
| Target | Beta subunit of bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Rifampicin is a bactericidal antibiotic that inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase, thereby preventing the initiation of RNA synthesis.
Approved indications
- Tuberculosis
Common side effects
- Hepatotoxicity
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB-106, Rifampicin CI brief — competitive landscape report
- AB-106, Rifampicin updates RSS · CI watch RSS
- Nuvation Bio Inc. portfolio CI